Nkarta Presents NKX019 Trial In Progress Poster At ASH 2021 Meeting

Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today presented a trial in progress poster on NKX019 for the treatment of relapsed and

Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today presented a trial in progress poster on NKX019 for the treatment of relapsed and refractory B-cell malignancies at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH).
 

NKX019 is an allogeneic and off-the-shelf investigational NK cell therapy candidate that builds on the innate anti-cancer biology of NK cells and their positive safety profile. Using NK cells selected from healthy donors, NKX019 is engineered to express a chimeric antigen receptor (CAR) targeting the B-cell antigen CD19 and membrane-bound IL-15 to augment the activity of the NK cells.

"Nkarta is pleased to share the details of the ongoing NKX019 Phase 1 clinical trial and its innovative multi-dose and multi-cycle treatment regimen with the clinical community," said Kanya Rajangam, MD, PhD, Chief Medical Officer of Nkarta. "Our vision is to establish new standards in cell therapy, integrating the power of innate immunology and the unique benefits of an engineered, off-the-shelf product to transform cancer treatment. The NKX019 clinical trial continues to advance at sites in Australia and the US, and we look forward to reporting initial data in 2022."

The poster outlines the design of a Phase 1 clinical trial (NCT05020678) evaluating the safety and anti-tumor activity of NKX019 as a multi-dose, multi-cycle monotherapy in patients with B-cell malignancies that express CD19, a well-validated B-cell cancer target. The presentation also includes preclinical data that demonstrate NKX019 retains its anti-tumor activity against cancer cell lines that express very low levels of CD19.

Poster Title: A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects with B-Cell Malignancies

Presenter: Michael Dickinson, MBBS, DMed Sci, FRACP, FRCPA, Peter MacCallum Cancer Centre and Royal Melbourne Hospital

Session: 704. Cellular Immunotherapies: Clinical: Poster III 

Date and Time: December 13, 2021, 6:00pm – 8:00pm ET

Publication Number: 3868

The poster is available on the ASH website and on the Nkarta website here. Additional information about the clinical trial is available on ClinicalTrials.gov.